Changes

</ref><ref name=":2" />. It shows hyperplasia of all three lineages, an increase in megakaryocyte count with dysplasia, and frequent abnormal karyotypes with chromosomal aneuploidy.  In the 2016 revision to the World Health Organization (WHO) classification system, acute panmyelosis with myelofibrosis is a distinct entity within the section of [:File:///C:/index.php/Acute Myeloid Leukemia (AML), Not Otherwise Specified Acute Myeloid Leukemia (AML), Not Otherwise Specified]<ref name=":0" /><ref name=":1" /><ref name=":2" />. This entity is distinct and does not meet the criteria for acute megakaryoblastic leukemia (AML-M7), myelodysplastic syndrome - refractory anemia with excess blast II ( MDS-RAEB-II) with fibrosis, primary myelofibrosis (PMF), AML with myelodysplasia related changes, or therapy-related AML. The clinical course of this entity is rapidly progressive, and the prognosis is poor with overall survival of only a few months (range 1.8–11.3 months).  

</ref><ref name=":2" />. It shows hyperplasia of all three lineages, an increase in megakaryocyte count with dysplasia, and frequent abnormal karyotypes with chromosomal aneuploidy.  In the 2016 revision to the World Health Organization (WHO) classification system, acute panmyelosis with myelofibrosis is a distinct entity within the section of [:File:///C:/index.php/Acute Myeloid Leukemia (AML), Not Otherwise Specified Acute Myeloid Leukemia (AML), Not Otherwise Specified]<ref name=":0" /><ref name=":1" /><ref name=":2" />. This entity is distinct and does not meet the criteria for acute megakaryoblastic leukemia (AML-M7), myelodysplastic syndrome - refractory anemia with excess blast II ( MDS-RAEB-II) with fibrosis, primary myelofibrosis (PMF), AML with myelodysplasia related changes, or therapy-related AML. The clinical course of this entity is rapidly progressive, and the prognosis is poor with overall survival of only a few months (range 1.8–11.3 months).  

This is a distinct entity in the World Health Organization (WHO) classification system within the section of [[Acute Myeloid Leukemia (AML), Not Otherwise Specified]]<ref name=":2">Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p165-166.</ref>.  This entity does ''not'' meet the criteria for inclusion in any of the other AML groups (''i.e.'' AML with Recurrent Genetic Abnormalities, AML with Myelodysplasia-Related Changes, or Therapy-Related Myeloid Neoplasms).

This is a distinct entity in the World Health Organization (WHO) classification system within the section of [[HAEM4:Acute Myeloid Leukemia (AML), Not Otherwise Specified]]<ref name=":2">Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p165-166.</ref>.  This entity does ''not'' meet the criteria for inclusion in any of the other AML groups (''i.e.'' AML with Recurrent Genetic Abnormalities, AML with Myelodysplasia-Related Changes, or Therapy-Related Myeloid Neoplasms).

==Synonyms / Terminology==

==Synonyms / Terminology==